Zuellig Pharma
Concise Prescribing Info
HTN. Heart failure (NYHA class II-IV) in patients receiving standard therapy eg, diuretics, digitalis & either ACE inhibitors or β-blockers but not both. Post-MI, in clinically stable patients w/ signs, symptoms or radiological evidence of left ventricular failure &/or w/ left ventricular dysfunction.
Dosage/Direction for Use
HTN 80 mg or 160 mg once daily. May be increased to 320 mg, or add a diuretic if BP is not adequately controlled. Heart failure 40 mg bid. May be uptitrated to 80 mg & 160 mg bid as tolerated. Max daily dose: 320 mg in divided doses. Post-MI Initially 20 mg bid as early as 12 hr after MI. Titrate to 40 mg, 80 mg, & 160 mg bid over the next few wk, or until a dose level of 80 mg bid 2 wk after treatment initiation is achieved. Target max dose in 3 mth: 160 mg bid.
May be taken with or without food.
Hypersensitivity. Concomitant use of angiotensin receptor antagonists or ACE inhibitors w/ aliskiren in patients w/ type 2 diabetes. Pregnancy.
Special Precautions
Correct Na &/or vol depletion prior to starting treatment. Monitor BUN & serum creatinine in patients w/ bilateral or unilateral renal artery stenosis. Patients w/ biliary obstructive disorders; heart failure or post-MI; evaluation of patients w/ heart failure or post-MI should always include renal function assessment. Concomitant use w/ ACE inhibitors & β-blocker in patients w/ heart failure. Discontinue if angioedema occurs. Concomitant use w/ drugs that block renin-angiotensin system eg, ACE inhibitors or aliskiren. Avoid concomitant use w/ aliskiren in patients w/ severe renal impairment (GFR <30 mL/min). Women of childbearing potential. Lactation.
Adverse Reactions
Dizziness, postural dizziness; hypotension, orthostatic hypotension; renal failure & impairment.
Drug Interactions
Increased incidence of hypotension, hyperkalemia & renal function changes w/ other drugs acting on renin-angiotensin system (eg, ARBs, ACE inhibitors, or aliskiren). Increased serum K & creatinine w/ K-sparing diuretics (eg, spironolactone, triamterene, amiloride), K supplements, or K-containing salt substitutes or other K level increasing drugs. Attenuated antihypertensive effect may occur w/ NSAIDs including selective cyclooxygenase-2 inhibitors. May increase serum lithium conc & toxicity. Increased systemic exposure w/ hepatic uptake transporter OATP1B1 inhibitors (eg, rifampin, cyclosporine) & hepatic efflux transporter MRP2 inhibitors (eg, ritonavir).
ATC Classification
C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Valpres FC tab 160 mg
Valpres FC tab 80 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in